Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In single and multiple ascending dose studies conducted on 30 and 22 healthy volunteers respectively, did not show any adverse effects on liver function
Subscribe to our email newsletter
Piramal Life Sciences has completed the phase-I clinical trials of a new drug for the treatment of diabetes – reported IANS.
The company said in a statement that the P1736, drug molecule, “is being developed for the treatment of type II diabetes. In the phase I trial, single and multiple ascending dose studies were conducted on 30 and 22 healthy volunteers respectively, in the Netherlands.”
The company revealed that the drug did not cause any adverse effects on liver function and did not cause blood plasma volume expansion or weight gain.
“Piramal Life Sciences aims to reduce the burden of disease by finding new and affordable cures for unmet medical needs. We are happy and proud that we have achieved this milestone in our quest to find a cure for type II diabetic patients,” reported the website quoting Swati Piramal, director of Piramal Group.